Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib (SUNITRES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03097601
Recruitment Status : Active, not recruiting
First Posted : March 31, 2017
Last Update Posted : October 8, 2019
Sponsor:
Collaborator:
Institut National de la Santé Et de la Recherche Médicale, France
Information provided by (Responsible Party):
Centre Antoine Lacassagne

Tracking Information
First Submitted Date March 27, 2017
First Posted Date March 31, 2017
Last Update Posted Date October 8, 2019
Actual Study Start Date June 2, 2016
Estimated Primary Completion Date December 30, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: March 27, 2017)
ELR+CXCL cytokines [ Time Frame: December 2018 ]
To determine of a threshold level of one or multiple ELR+CXCL cytokines indicative of progression for routine clinical practises
Original Primary Outcome Measures Same as current
Change History Complete list of historical versions of study NCT03097601 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures
 (submitted: March 27, 2017)
molecular mechanisms [ Time Frame: December 2020 ]
To decipher the molecular mechanisms implicated in ELR+CXCL cytokines expression at the basal level and at progression on sunitinib. Expression of these cytokines by tumor cells and cells from the microenvironment (especially the Macrophages M1/Macrophages M2 ratio).
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib
Official Title ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib and New Relevant Therapeutic Targets in Refractory Patients
Brief Summary Metastatic renal cell carcinomas (mRCC) are highly angiogenic tumors because of mutation of the pVHL gene leading to over-expression of VEGF. Therefore, mRCC represent a paradigm for the use of anti-angiogenic treatments targeting the VEGF/VEGFR pathway. Despite an increase of the time to progression these treatments, taken alone, are not curative with ineluctable progression especially for the reference treatment sunitinib a multi kinase inhibitors of VEGF, PDGF, CSF1 receptors and c-kit, FLT3 and RET. At progression on sunitinib, patients received mTOR inhibitors which is responsible, at least, of HIF1A mRNA translation, then on a third line sorafenib that inhibits VEGFR2, 3 PDGFR, c-KIT and B-RAF. The access to these different lines of treatment has finally prolonged survival but this situation is not satisfactory. Unexpected aspect associated with the use of anti-angiogenesis treatments was the diversity of the patients' response. Some patients are right away refractory and die rapidly, but the majority of patient has a transient response then progress and a few percentages of them are responder for a very long period of time. By only targeting normal endothelial cells and tumor neo-vascularization, the response should have been more homogenous, thus highlighting that the treatment induced a "Darwinian" adaptation of tumor cells and cells of the microenvironment. Two conclusions follow from these observations: 1- The need to identify predictive markers of efficacy; 2-The identification of druggable targets participating in progression on anti-angiogenic treatments. Our results have highlighted the ELR+CXCL cytokines, pro-inflammatory and pro-angiogenic cytokines as prognosis markers of survival of mRCC patients and relevant therapeutic targets on experimental tumors in mice. As VEGF/VEGFR, these cytokines are produced by tumor, endothelial and inflammatory cells. Their receptors (CXCR1, 2) are expressed physiologically by immune and endothelial cells and aberrantly by tumor cells generating at the same time autocrine proliferation loops, chronic angiogenesis and inflammation. Therefore, the CXCL/CXCR1,2 axis constitutes an independent axis of cancer development and propagation. However, the current standard of care is to administer anti-angiogenic therapies as the first line treatment. The objective of this project is linked to the identification of potent predictive markers of efficacy, easily measured in plasma samples. Deciphering the molecular mechanisms associated with the production of such cytokines by tumor cells and by cells of the microenvironment represents an interesting intellectual challenge and a relevant way to improve the current treatments by targeting, at progression on the current standard of care, other pathways than the VEGF/VEGFR axis.
Detailed Description

Metastatic renal cell carcinomas (mRCC) are highly angiogenic tumors because of mutation of the pVHL gene leading to over-expression of VEGF. Therefore, mRCC represents a paradigm for the use of anti-angiogenic treatments targeting the VEGF/VEGFR pathway. Despite an increase of the time to progression these treatments, administered alone, are not curative with ineluctable progression especially for the reference treatment sunitinib a multi kinase inhibitors of VEGF, PDGF, CSF1 receptors and c-kit, FLT3. At progression with sunitinib treatment, patients received mTOR inhibitors which is responsible, at least, of HIF1A mRNA translation, then through a third line sorafenib that inhibits VEGFR2, 3 PDGFR, c-KIT and B-RAF. The access to these different lines of treatment has finally prolonged survival but this situation is not satisfactory. New way of thinking and new therapeutic targets are necessary to "chronisize" the pathology or even to cure it. The current therapeutic practises are based on the statement that the treatments must destroy blood vessels to asphyxiate the tumors and that endothelial cells are normal cells that cannot adapt to the selection pressure exerted by the treatments. These statements arewrong since tumor cells aberrantly express the receptors targeted by anti-angiogenic drugs leading to cell adaptation and tumor recurrence. Another unexpected aspect associated with the use of anti-angiogenesis treatments was the diversity of the patients'response. Some patients are right away refractory and die rapidly, but the majority of patients has a transient response then progress and a few percentages of them are responders for a very long period. By only targeting normal endothelial cells and tumor neo-vascularization, the response should have been more homogenous. 3 conclusions follow from these observations: 1- The need to identify predictive markers of efficacy; 2-The identification of druggable targets participating in progression on anti-angiogenic treatments; 3- These targets should be independent of the VEGF/VEGFR axis.

The results have highlighted the ELR+CXCL cytokines, pro-inflammatory and pro-angiogenic cytokines as prognosis markers of survival of mRCC patients and relevant therapeutic targets on experimental tumors in mice. As VEGF/VEGFR, these cytokines are produced by tumor, endothelial and inflammatory cells. Their receptors (CXCR1, 2) are expressed physiologically by immune and endothelial cells and aberrantly by tumor cells generating at the same time autocrine proliferation loops, chronic angiogenesis and inflammation. Therefore, the CXCL/CXCR1,2 axis constitutes an independent axis of cancer development and propagation. However, the current standard of care is to administer anti-angiogenic therapies as the first line treatment. Hence, what is the relevance of CXCL cytokines as predictive markers of sunitinib efficacy, and what are the mechanisms linked to the production of CXCL cytokines by mRCC or in response to treatments?. Deciphering the molecular mechanisms associated with the production of such cytokines by tumor cells and by cells of the microenvironment represents an interesting intellectual challenge and a relevant way to improve the current treatments by targeting, at progression on the current standard of care, other pathways than the VEGF/VEGFR axis.

This project aimed at the improvement of current clinical practises for mRCC. Numerous efforts have been given to the determination of prognosis markers for different tumors including mRCC. However, for clinical practises, physicians are more interested to predictive markers of success/failure of a treatment that to biological prognosis markers that are most of the time as indicative as classical clinical parameters (TNM for example). The recent experiments have highlighted relevant cytokines (ELR+CXCL) participating in the aggressiveness of mRCC. Indeed, the intra-tumor amounts of the ELR+CXCL cytokine CXCL7 was a potent prognosis marker of survival independent of any clinical parameters. Therefore it was indicative of poor prognosis for patients who were a priori of good prognosis according to the TNM or the Fuhrman grade (consideration of nuclear and nucleolus size). We have also demonstrated the prognosis value of two other ELR+CXCL cytokine CXCL1, CXCL5 and CXCL8. Both of them are not independent of clinical parameters. However, their role as predictive markers of resistance to anti-angiogenic drugs, the current standard of care, is still unknown.

For a medical point of view, a rapid identification of responders and no-responders is of first importance. It will avoid undesired toxic events for unresponsive patients and a rapid adaptation of the treatment considering that different lines of therapies are currently available for mRCC patients. The determination of a threshold value for the most relevant cytokines is needed and this threshold must be determined of independent cohort of patients for a better reliability. Such test should not be invasive for the patients and as simple as possible in order to introduce in clinical practises for a low price that can be reimburse by the social security. It is compatible with what we propose to do by measuring ELR+CXCL levels on blood samples with classical ELISA tests.

Deciphering the mechanisms at the origin of the de novo synthesis of redundant pro-angiogenic/pro-inflammatory cytokines under the selection pressure of treatment targeting the VEGF/VEGFR pathway is intellectually challenging and may identify unknown parameters implicated in Darwinian adaptation of tumor cells among a very heterogeneous environment.

The main objectives are :

  • Research helping to the understanding of biological mechanisms from clinical observations (Bed to Bench) and the transfer of knowledge from the clinic to the laboratories (bed to bench).
  • Research helping to the prognosis.
  • Research helping to the therapeutic decision and treatment monitoring.
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
Description:
Experiment on cell lines, on human samples and animal models. CXCL cytokines as predictive markers of sunitinib efficacy in order to demonstrate the mechanisms linked to the production of CXCL cytokines by mRCC or in response to treatments
Sampling Method Non-Probability Sample
Study Population patients with mRCC and treated by sunitinib after radical nephrectomy
Condition Metastatic Kidney Cancers
Intervention Diagnostic Test: ELR+CXCL cytokines levels are of sunitinib response
Demonstrate on independent cohorts of patients that ELR+CXCL cytokines levels are of sunitinib response
Study Groups/Cohorts sunitinib cohort
independent cohorts of patients who received sunitinib for metastic kidney cancer, on who we intend to demonstrate that ELR+CXCL cytokines levels are of sunitinib response
Intervention: Diagnostic Test: ELR+CXCL cytokines levels are of sunitinib response
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Active, not recruiting
Actual Enrollment
 (submitted: March 27, 2017)
60
Original Actual Enrollment Same as current
Estimated Study Completion Date December 30, 2019
Estimated Primary Completion Date December 30, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • patients with mRCC and treated by sunitinib after radical nephrectomy included in SUVEGIL 8 Clinical Trial (Sponsor : Centre Antoine Lacassagne)

Exclusion Criteria:

  • Non applicable
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries France
Removed Location Countries  
 
Administrative Information
NCT Number NCT03097601
Other Study ID Numbers 2016/09
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party Centre Antoine Lacassagne
Study Sponsor Centre Antoine Lacassagne
Collaborators Institut National de la Santé Et de la Recherche Médicale, France
Investigators
Study Director: Christine LOVERA Centre Antoine Lacassagne
PRS Account Centre Antoine Lacassagne
Verification Date October 2019